Navigation Links
CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine
Date:10/22/2013

; It selectively targets 5-HT1F receptors expressed in the trigeminal pathway.  Its novel chemical class and differentiated site and mechanism of action led to Lasmiditan's designation as a "ditan", a new drug class, by the INN.

CoLucid has successfully completed six clinical studies for Lasmiditan, including a Phase 2b study treating a single migraine attack in 391 patients, as well as a TQTc study.

Phase 3 development will address two major unmet needs in patients who are poorly served by currently available therapies:

  • Patients with risk factors for cardiovascular disease and those with cardiovascular disease
  • Patients who have not had adequate response to triptans

ABOUT MIGRAINE

Migraine is ranked as the seventh highest cause of global disability and in the top 10 causes of disability in 14 of 21 world regions studied, according to findings by the Global Burden of Disease Survey 2010 conducted by the World Health Organization. It is the leading cause of disability among neurological disorders.  Some 36 million Americans have migraine, more than have asthma or diabetes combined.  Migraine can be extremely disabling and costly, accounting for more than $20 billion in direct (e.g. doctor visits, medications) and indirect (e.g. missed work, lost productivity) expenses each year in the United States. The prevalence of migraine in Asia is approximately 9%, and in South Korea alone, it is 6%.  According to statistics available from the Health and Insurance Review Agency (HIRA), in 2012 more than 500,000 patients were diagnosed with migraine in Korea, with women accounting for 72% of these numbers.

ABOUT COLUCID PHARMACEUTICALS, INC.

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide
'/>"/>

SOURCE CoLucid Pharmaceuticals, Inc; ILDONG Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
(Date:12/24/2014)... China , Dec. 23, 2014 ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today announced that the Company ... its Good Manufacturing Practice (GMP) certificate of TPI,s ... Drug Administration,s (CFDA). The public notice period is ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
(Date:12/25/2014)... updated its blog to provide professional shopping tips on wedding and ... LunaDress.co.uk come with big discounts, up to 80 percent off. , ... to be a most exciting memory and can show off a ... a wedding. On the updated fashion blog, ladies can now find ... day . , Going out with friends to a party is ...
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... 2007) Lower muscle mass and an increase in body ... exercise is a proven way to prevent the loss of ... Mark Tarnopolsky shows that taking a combination of creatine monohydrate ... exercise training provides even greater benefits. , The ...
... 2 Speaker Nancy Pelosi,released the following statement ... The Speaker was presented the National Breast,Cancer Coalition,s ... York City last,night: "National Breast Cancer Awareness ... and to recommit ourselves to advancing prevention, improving,treatments, ...
... imagine iPhones, laptops and flash drives. But more ... a newly updated inventory of nanotechnology consumer products ... and health products. , Maintained by the ... inventory includes Head NanoTitanium Tennis Racquets, Eddie Bauer ...
... is a statement,by Linda A. Suydam, D.P.A., president ... to inaccurate and misleading media reports,surrounding the U.S. ... Nonprescription Drugs Advisory Committee and Pediatric Advisory,Committee scheduled ... the makers of pediatric, over-the-counter cough and cold,medicines ...
... WASHINGTON, Oct. 2 Speaker Nancy Pelosi and,Senate Majority ... sending President Bush the Children,s Health Insurance,Program (CHIP) legislation:, ... a bipartisan bill,to insure 10 million of our nation,s ... American people that the President will sign the bill ...
... Offer Both Suspension and Tablet Forms, PRINCETON, N.J., ... subsidiary of Ranbaxy Laboratories Limited (RLL),announced today that RLL ... Administration (U.S. FDA) to manufacture and market Clarithromycin for,Oral ... Ranbaxy is the first,company to have been granted a ...
Cached Medicine News:Health News:Nanotechnology: not just for geeks 2Health News:Statement from the Consumer Healthcare Products Association on the Safety of Pediatric Over-the-Counter Medicines 2Health News:Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP 2
Suitable for mild to moderate ACL and/or PCL, MCL and LCL instabilities, this neoprene brace with extended hinge bars is an ideal intermediate-level product that can be used in sporting activities. C...
Provides range-of-motion control for both flexion and extension along with a drop lock feature...
Provides comfortable compression, support and immobilization for the knee...
Dynamic brace that provides a low load, prolonged stretch to the connective tissue around the joint using an adjustment hinge with a built-in tension spring...
Medicine Products: